Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735

Abstract

With longer follow-up, four cycles of TC was superior to standard AC (DFS and OS) and was a tolerable regimen in both older and younger patients.

Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer

“…Later, anthracycline combinations were found to be slightly but significantly more effective than the CMF regimen [2]. More recently, several adjuvant phase III trials have shown that taxane regimens further reduce the likelihood of recurrence and death, compared to anthracycline-containing combinations [3][4][5][6][7][8][9][10], but the absolute benefit was again small, and some trials were unable to show any advantage for the taxane arm [11,12]. Taxanes and anthracyclines can induce some acute and chronic toxicities of considerable clinical concern.…”

Controversial issues in the management of older adults with early breast cancer

“…Nevertheless, taxanes may be given as an alternative to anthracyclines to alleviate cardiac risks. Use of docetaxel and cyclophosphamide (TC) has provided a significant survival benefit over AC after 7 years median follow-up, irrespective of age [52]. Although febrile neutropenia may be an issue, this can be minimized with granulocyte colony stimulating factors (G-CSF) primary prophylactic administration [53,54].…”

Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel

“…An anthracycline-free taxane doublet (docetaxel/cyclophosphamide) demonstrated superior disease-free and overall survival compared with doxorubicin/cyclophosphamide in the treatment of early stage breast cancer with an acceptable safety profile, with grade 3/4 neutropoenia of 61% and no cardiotoxicity [48]. As a consequence, a multicenter Phase II (8) pilot trial of weekly nab-P/cyclophosphamide was conducted to test the safety and tolerability of this combination in early-stage breast cancer.…”